Sure, each situation needs to be assessed on its own merits but, in general, P2 results haven't been shown to be all that predictive of P3 success. The reality is that since 2007 the Phase III failure rate for new drugs has been around 50%. The # 1 reason (66%) is due to lack of efficacy. I'm fairly certain that these drugs all showed positive efficacy in their P2 trials as well ;)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.